
Opinion|Videos|March 7, 2025
Molecular Profiling in MPNs: Enhancing Diagnostic Insights
Author(s)Daniel Landau, MD
An expert discusses what stands out most about this patient’s molecular profile and how these insights enhance the diagnostic approach in myeloproliferative neoplasms (MPNs).
Advertisement
Episodes in this series

Video content above is prompted by the following:
Please share what impresses you most about this patient’s molecular profile and how these insights enhance your diagnostic approach in MPNs.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
Optimizing Second-Line Therapy in Metastatic ccRCC
5























